高放射性:锆-89是一种常用于正电子发射断层扫描(PET)的放射性同位素。 高水溶性和生物相容性:PEG修饰提高了化合物的水溶性和在体内的生物相容性。 综上所述,MTzL/BCNL、3,6-二甲酯基-1,2,4,5-四嗪以及[Zr-89]Zr-DFO-PEG(5)-Tz([Zr-89]Zr-DFO-PEG(5)-Tetrazine)都是具有特定结构和性质的化合物,...
Here, we demonstrate that89Zr-DFO*-immuno-PET can be used to visualize and quantify brain uptake of mAbs and contribute to the evaluation of biological therapeutics for brain diseases.doi:10.1007/s00259-023-06109-3N. Stergiougrid.12380.380000 0004 1754 9227Radiology & Nuclear MedicineAmsterdam UMC...
Zr-89 MSTP2109A, a humanized antibody targeting STEAP1 conjugated with desferrioxami... JA Carrasquillo,DC Danila,V Beylergil,... - 《Cancer Research》 被引量: 2发表: 2014年 Imaging metastatic castration-resistant prostate cancer patients with 89 Zr-DFO-MSTP2109A anti-STEAP1 antibody Six-...
Lesion detection by [ 89 Zr]Zr-DFO-girentuximab and [ 18 F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinomaLesion detection by [ 89 Zr]Zr-DFO-girentuximab and [ 18 F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinomaCAIXClear...
This result is in agreement with the low uptake of Zr-89-DFO-cetuximab in FCR cells. Tumor uptake of Zr-89-DFO-cetuximab in FCR was significantly lower than FCS tumors (p = 0.0340). Conclusions: In this work, the authors showed that Zr-89-DFO-cetuximab is suitable for identification of...
[89Zr]Zr-DFO-denosumab immuno-PET validation in the tumor microenvironment of human ME-180 xenograftsdoi:10.1016/S0969-8051(21)00270-5Jonatan DewulfChristel VangestelTim Van den WyngaertFilipe ElvasElsevier BVNuclear Medicine and Biology
Preparation of 89Zr - DFO - Cetuximab for Imaging of EGFR - Expressing TumorsZolghadri, SamanehMohammadpour-Ghazi, FatemehYousefnia, HassanReports of Radiotherapy & Oncology
A biodistribution study revealed excellent stability of [89Zr]Zr-DFO-nimotuzumab in vivo compared with 89Zr as a bone seeker. High uptake in the liver and heart and modest penetration in the brain were observed, with no significant accumulation of activity in other organs. ImmunoPET studies ...
Development of 89Zr - DFO - Bevacizumab for PET Imaging of VEGF TumorsMohammadpour-Ghazi, Fatemehzolghadri, SamanehYousefnia, HassanReports of Radiotherapy & Oncology
The purpose of this study is to develop(89)Zr-labeled amivantamab as a potential companion diagnostic imaging agent to amivantamab therapy using various preclinical models of TNBC for evaluation. Methods Amivantamab was conjugated to desferrioxamine (DFO) and radiolabeled with(89)Zr to obtain [...